|
|
Profile
|
Delegates :
Tetsuya Mishima |
|
Incorporated :
August 9 , 2004 |
Paid in Capital :
100 Million yen |
Employees :
20 人 |
Address :
Yaesu KH bldg. 4th Fl. 19-8 Nihonbashi Kabutocho, Chuo ku TOKYO
〒1030026
|
TEL/FAX :
+81-3-5642-8081 / +81-3-5642-8082 |
URL：
anaeropharma.co.jp |
Attachment :
|
Mission/Background :
Anaeropharma is a biopharmaceutical company engaged in research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant bifidobacterium. This approach offers broad potential to be more effective to solid tumors and less toxic to healthy tissues than conventional anti-cancer drugs. The fundamental technology to create such drug candidates was invented by researchers at Shinshu University, Nagano, Japan. |
|
Technology & Business
|
The majority of human solid tumors contain regions of acute or chronic hypoxia, mainly due to insufficient and unusual angiogenesis. These microenvironments cause decreased uptake of chemotherapeutic drugs. APS001F is a living recombinant bifidobacterium to express the cytosine deaminase (CD) gene. Bifidobacterium is a non-pathogenic obligate anaerobe and a major component of normal human intestinal flora. When APS001F is administered intravenously, APS001F localizes and grows in the hypoxic regions of tumors. 5-FC, which is administered orally, is converted to 5-FU, an active anti-tumor agent, by the CD enzyme expressed by APS001F in tumors. The novel therapy is expected to have the advantage of limiting the systemic toxicity of 5-FU. It also allows 5-FU to achieve high concentration in tumors, which results in clear anti-tumor efficacy. The company is also developing other drug candidates in oncology and other ischemic disease areas.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
APS001F
|
Phase1
|
Anti-cancer drug for solid tumors -- CD enzyme expressing recombinant bifidobacterium
|
To complete Phase I trial and obtain safety and efficacy data
|
Recombinant bifidobacterium drugs in oncology
|
Preclinical
|
Anti-immuno check point molecules antibody expressing and cytokine expressing bifidobacterium
|
To perform non-clinical studies and complete pertnering
|
FGF2 produsing bifidobacterium for ischemic disease
|
Preclinical
|
FGF2 produsing recombinant bifidobacterium drug for the indication of critical limb ischemia
|
To perform non-clinical studies and complete pertnering
|
|
|
|
|
|
|
|
|
|
Highlights
|
The clinical study of APS001F is going well in the US. Anti-immuno checkpoint antibody producing bifidobacterium was revealed at the AACR annual meeting in 2015.
|
|
Alliance strategy
|
The company pursues co-development and licensing partnership with pharmaceutical companies with regard to its projects, and co-research setting based on its platform technology utilizing bifidobacterium.
|
|
|